Efficacy and safety of the interleukin-12/interleukin-23 antagonist ustekinumab in Korean patients with moderate to severe psoriasis - 09/05/15
Young Lip Park, MD, PhD, Department of Dermatology, Soonchunhyang University College of Medicine, Bucheon-si, Gyeonggi-do, South Korea; Kyung OKim, MD, Department of Dermatology, Soonchunhyang University College of Medicine, Bucheon-si, Gyeonggi-do, South Korea; Ye Seul Kim, MD, Department of Dermatology, Soonchunhyang University College of Medicine, Bucheon-si, Gyeonggi-do, South Korea; Bum Joon Ko, MD, Department of Dermatology, Soonchunhyang University College of Medicine, Seoul, South Korea; Euy Hyun Chung, MD, Department of Dermatology, Soonchunhyang University College of Medicine, Cheonan-si, Chungcheongnam-do, South Korea
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 72 - N° 5S1
P. AB233 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?